Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics DOI Open Access

Zhengyuan Qiu,

Dalin Zhang,

Fernando Jose Garcia-Marques

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1361 - 1361

Published: April 18, 2025

Background/Objectives: Clear-cell renal cell carcinoma (ccRCC) is a heterogenous disease that can be classified into multiple molecular subtypes with differential prognosis and sensitivities to treatments based on their genomic, transcriptomic, proteomic, metabolic profiles. Patient-derived xenografts (PDXs) are high-fidelity cancer models because they maintain similar genotypes immunohistologic phenotypes the parental tumors respond standard-of-care therapies as expected. However, whether identified in ccRCC patient samples preserved PDX not clear. Our objective compare transcriptional proteomic profiles of our those patients identify both similarities distinctions between corresponding subtypes, so proper used when investigating subtypes. Methods: To match PDXs human we compared transcriptomic five established lab reported by group, well other groups, using hierarchical analysis, Principal Component Analysis (PCA), Permutation Correlation Analysis. The enrichment key pathways was determined Gene Set Enrichment Results: We found each resembles one closely at transcript protein levels. In addition, representing different show unique characteristics. Moreover, correlated pathway activities implicated progression therapy resistance. Conclusions: results suggest should mechanism resistance for This “matching” strategy will greatly facilitate clinical translation positive findings optimal management patients.

Language: Английский

Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics DOI Open Access

Zhengyuan Qiu,

Dalin Zhang,

Fernando Jose Garcia-Marques

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1361 - 1361

Published: April 18, 2025

Background/Objectives: Clear-cell renal cell carcinoma (ccRCC) is a heterogenous disease that can be classified into multiple molecular subtypes with differential prognosis and sensitivities to treatments based on their genomic, transcriptomic, proteomic, metabolic profiles. Patient-derived xenografts (PDXs) are high-fidelity cancer models because they maintain similar genotypes immunohistologic phenotypes the parental tumors respond standard-of-care therapies as expected. However, whether identified in ccRCC patient samples preserved PDX not clear. Our objective compare transcriptional proteomic profiles of our those patients identify both similarities distinctions between corresponding subtypes, so proper used when investigating subtypes. Methods: To match PDXs human we compared transcriptomic five established lab reported by group, well other groups, using hierarchical analysis, Principal Component Analysis (PCA), Permutation Correlation Analysis. The enrichment key pathways was determined Gene Set Enrichment Results: We found each resembles one closely at transcript protein levels. In addition, representing different show unique characteristics. Moreover, correlated pathway activities implicated progression therapy resistance. Conclusions: results suggest should mechanism resistance for This “matching” strategy will greatly facilitate clinical translation positive findings optimal management patients.

Language: Английский

Citations

0